Protein‐misfolding diseases and chaperone‐based therapeutic approaches

@article{Chaudhuri2006ProteinmisfoldingDA,
  title={Protein‐misfolding diseases and chaperone‐based therapeutic approaches},
  author={Tapan K. Chaudhuri and Subhankar Paul},
  journal={The FEBS Journal},
  year={2006},
  volume={273}
}
A large number of neurodegenerative diseases in humans result from protein misfolding and aggregation. Protein misfolding is believed to be the primary cause of Alzheimer's disease, Parkinson's disease, Huntington's disease, Creutzfeldt–Jakob disease, cystic fibrosis, Gaucher's disease and many other degenerative and neurodegenerative disorders. Cellular molecular chaperones, which are ubiquitous, stress‐induced proteins, and newly found chemical and pharmacological chaperones have been found… 
Chemical Chaperone and Inhibitor Discovery: Potential Treatments for Protein Conformational Diseases
TLDR
It is believed that a better understanding of the mechanisms of conformational changes as well as the biological functions of these proteins will lead to the development and design of potential interfering compounds against amyloid formation associated with protein conformational diseases.
Targeting chaperones, heat shock factor-1, and unfolded protein response: Promising therapeutic approaches for neurodegenerative disorders
TLDR
The chaperones network and different approaches as the therapeutic targets for neurodegenerative diseases are described and the roles of molecular, chemical, and pharmacological chaperONES, as well as heat shock factor-1 and the unfolded protein response are discussed in detail.
Emerging novel concept of chaperone therapies for protein misfolding diseases
  • Yoshiyuki Suzuki
  • Biology, Medicine
    Proceedings of the Japan Academy. Series B, Physical and biological sciences
  • 2014
TLDR
Active-site binding low molecular competitive inhibitors (chemical chaperones) paradoxically stabilized and enhanced the enzyme activity in somatic cells by correction of the misfolding of enzyme protein, and reached the brain through the blood-brain barrier after oral administration, and corrected pathophysiology of the disease.
[Pharmacological chaperones: a potential therapeutic treatment for conformational diseases].
TLDR
Pharmacological chaperones have obviously a therapeutic potential to treat rare diseases like cystic fibrosis, retinitis pigmentosa, nephrogenic diabetes insipidus, Fabry disease, Gaucher disease, but also for cancers and more frequent and highly invalidant neurodegenerative disorders such as Alzheimer's disease or Parkinson's disease.
Dealing with Misfolded Proteins: Examining the Neuroprotective Role of Molecular Chaperones in Neurodegeneration
TLDR
The role of molecular chaperones in neurodegenerative diseases is discussed, highlighting their functional classification, regulation, and therapeutic potential for such diseases.
Protein aggregation, misfolding and consequential human neurodegenerative diseases
TLDR
The present review deals with the human neurodegenerative diseases caused due to the protein misfolding highlighting pathomechanisms and therapeutic intervention.
Novel therapeutic strategies for the treatment of protein-misfolding diseases
  • J. Rochet
  • Chemistry, Medicine
    Expert Reviews in Molecular Medicine
  • 2007
TLDR
Three promising approaches include: inhibiting protein aggregation with peptides or small molecules identified via structure-based drug design or high-throughput screening; interfering with post-translational modifications that stimulate protein misfolding and aggregation; and upregulating molecular chaperones or aggregate-clearance mechanisms.
Protein folding and misfolding in the neurodegenerative disorders: a review.
TLDR
This review gives an outline regarding the role of protein misfolding in the molecular and cellular mechanisms in the pathogenesis of Alzheimer's and Parkinson along with their treatment possibilities.
Protein Misfolding and Aggregation: The Relatedness between Parkinson’s Disease and Hepatic Endoplasmic Reticulum Storage Disorders
TLDR
The pathological bases leading to misfolding and aggregation of proteins involved in PD, AATD, and HHHS are reviewed and clinical perspectives regarding possible common treatments focused on improving the defensive responses to protein aggregation for diseases as different as PD, and ERSDs are reviewed.
Polyglutamine-mediated neurodegeneration: Use of chaperones as prevention strategy
  • S. Paul
  • Biology, Medicine
    Biochemistry (Moscow)
  • 2007
TLDR
The roles of the ubiquitin—proteasome pathway and molecular chaperones in the development of polyglutamine diseases and probable approach for the prevention of many of these fatal disorders using molecular chapers as a therapeutic agent are discussed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 174 REFERENCES
Protective effect of chaperones on polyglutamine diseases
TLDR
Overexpression of chaperones reduces aggregate formation and suppresses apoptosis in several polyglutamine disease models including spinal and bulbar muscular atrophy, indicating that chaperone may be one of the key factors in the development of polyglUTamine disease, and suggesting that increasing expression level or enhancing the function of chapers will provide an avenue for the treatment ofpolyglutamines disease.
Roles of molecular chaperones in protein misfolding diseases.
TLDR
Increased chaperone expression can suppress the neurotoxicity of these molecules, suggesting possible therapeutic strategies.
Protein misfolding in Alzheimer’s and Parkinson’s disease: genetics and molecular mechanisms
TLDR
The results on the role of protein misfolding in AD and PD and the influence of mutations associated with these diseases on the expression of amyloidogenic proteins are reviewed.
Neurodegenerative disorders of protein aggregation
  • B. Shastry
  • Medicine, Biology
    Neurochemistry International
  • 2003
TLDR
In future, an understanding of the causes of protein aggregation and genetic and environmental susceptibility factors of a specific individual (or specific individual determinants) may provide a better opportunity for an effective therapeutic intervention.
Cellular Defenses against Unfolded Proteins A Cell Biologist Thinks about Neurodegenerative Diseases
1993; Massa et al., 1996). Intracellular inclusions of de-natured proteins are also characteristic features of many neurological diseases, including Amyotrophic Lateral Sclerosis, Alzheimer's
Role of quality control pathways in human diseases involving protein misfolding.
  • W. Welch
  • Biology, Medicine
    Seminars in cell & developmental biology
  • 2004
TLDR
In many cases simply altering the protein folding environment within the cell can effectively rescue the maturation and stability of the mutant protein and thereby reduce the onset and/or progression of the disease phenotype.
Therapeutic approaches to protein-misfolding diseases
TLDR
Several sporadic and genetic diseases are caused by protein misfolding, and a unified view of the molecular and cellular pathogenesis has led to the search for chemical chaperones that can slow, arrest or revert disease progression.
Protein Misfolding, Amyloid Formation, and Neurodegeneration A Critical Role for Molecular Chaperones?
TLDR
Recent studies have revealed a critical role for molecular chaperones in several neurodegenerative disorders, including Alzheimer's, Parkinson's and Huntington's disease.
From Alzheimer to Huntington: why is a structural understanding so difficult?
TLDR
The structural knowledge accumulated for two paradigmatic misfolding disorders, Alzheimer's disease (AD) and the family of poly‐glutamine diseases (poly‐Q) are compared and some of the hypotheses suggested for explaining aggregate formation are discussed.
Pharmacological chaperones: a new twist on receptor folding.
TLDR
The discovery that ligands with pharmacological selectivity (pharmacological chaperones) can rescue the proper targeting and function of misfolded proteins, including receptors, might help to develop new treatments for 'conformational diseases'.
...
1
2
3
4
5
...